Atebrioz (zilurgisertib) is an oral activin receptor-like kinase 2 (ALK2) inhibitor indicated to reduce the volume of new heterotopic ossification in adults and pediatric patients 12 years of age and older with fibrodysplasia ossificans progressiva (FOP).
FOP is a rare genetic disorder in which connective tissues such as muscles, tendons, and ligaments progressively transform into bone. By inhibiting ALK2 signaling, Atebrioz targets a pathway involved in abnormal bone formation. Atebrioz provides a targeted treatment option for fibrodysplasia ossificans progressiva, a progressive disorder that can lead to severe mobility limitations and disability.
By reducing new heterotopic bone formation, the therapy addresses an important feature of disease progression rather than treating symptoms alone. Its approval expands treatment options for patients living with this rare genetic disorder and addresses a significant unmet medical need.
